Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > A nice report on Trogarzo on a Spanish patient

<< Previous

Bullboard Posts

Next >>

Post by SPCEO1on Sep 22, 2022 10:00am

248 Views

Post# 34978723

A nice report on Trogarzo on a Spanish patient

https://academicmedicaleducation.com/meeting/european-meeting-hiv-hepatitis-2022/abstract/viral-load-suppression-after-three-year

Hopefully, that patient is still able to get Trogarzo. I wonder if European patients are now delivered their drug from TH in the US or from Taimed? I suspect the latter since TH gave back their rights.

<< Previous

Bullboard Posts

Next >>

F3 Uranium yields ultra-high grades in Saskatchewan